staceywhite, Author at European Medical Journal - Page 15 of 195

Review of HLTH Europe 2025

EUROPE’s number one healthcare innovation event, HLTH Europe, was held this year in Amsterdam, the Netherlands, from the 16th–19th June…

HLTH Europe 2025: Where Vision Meets Action

IT IS with genuine pleasure and a full heart that I reflect on HLTH Europe 2025, an event that did more than bring together healthcare…

Broadening Horizons in Health Innovation: Insights from HLTH Europe 2025

NOW IN its seventh year, HLTH has evolved into a global bellwether for innovation in healthcare. HLTH Europe 2025 convened over 12,000…

HLTH Europe 2025 Interview: Aiga Balode

Aiga Balode – Deputy State Secretary for Digitalization and Change Management, Ministry of Health of the Republic of Latvi – During the…

CLL Highlights from EHA 2025

This review article explores key research highlights and new data on CLL presented at EHA 2025, considering how the latest clinical…

Gene Therapy: Living With(out) Haemophilia?

Since research on human gene therapy began, the expectations regarding its potential in treating haemophilia have been high. Haemophilia…

Ranking Treatments for Lenalidomide-Refractory Multiple Myeloma post DRd

Multiple myeloma is the second most common haematological malignancy, with an increasing global incidence…

Re-evaluating European Haemophilia Standards

TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…

The Immunotherapy Landscape for Multiple Myeloma

Take a look at our latest haematology infographic, which explores the current immunotherapy treatment landscape for multiple myeloma…

Rituximab in Adults with Autoimmune Haematological Disorders

Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…